3 edition of Drug resistance in leukemia and lymphoma II found in the catalog.
Drug resistance in leukemia and lymphoma II
Includes bibliographical references and indexes.
|Statement||edited by R. Pieters, G.J.I. Kaspers, and A.J.P. Veerman.|
|Series||Advances in blood disorders -- v. 3|
|Contributions||Kaspers, G. J. L., 1963-, Pieters, R., Veerman, A. J. P.|
|LC Classifications||RC271.C5 D78 1997|
|The Physical Object|
|Pagination||xiii, 484 p. :|
|Number of Pages||484|
Overview of lymphoma, including types such as Hodgkin and non-Hodgkin, and related tests. Overcoming drug resistance in leukemia using a novel integrin alpha4 inhibitor, AVA The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies; Molecular Pharmacology, Drug Resistance-Lymphoid and Other Diseases I; Molecular Pharmacology, Drug Resistance-Lymphoid and Other Diseases II; Acute Lymphoblastic Leukemia: Clinical Studies: Novel Therapies; This drug has received extensive support from LLS: over $4M in 9 grants for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma and for multiple myeloma. Earlier this year in March, the FDA approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients.
The expression of multidrug resistance gene 1 (MDR1), B-cell-specific Moloney murine leukemia virus insertion site 1 (BMI1), topoisomerase II (Topo II) and multidrug resistance-related protein 1 (MRP1) mRNA and protein were analyzed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blotting, respectively. Although diffuse large B-cell lymphoma (DLBCL) is highly curative, treatment failure remains a major therapeutic challenge. Historically, a variety of strategies aimed at overcoming specific drug resistance mechanisms have been attempted but with limited success.1, 2 Their rationale derived from classical concepts of drug resistance, which hypothesize that the acquisition of drug .
Christ is passing by
Nomination of James R. Moseley
A testimony concerning the works of the living God, shewing how the mysteries of his workings hath worked many wayes in and amongst mankind, or, The knowledge of God revealed which shews the way from the bondage of darkness into the liberty of the Sons of God
High redshift QSOs and the X-ray background
Investigation of the cellular effects of low intensity laser irradiation (LILI).
Handbook of Natural Beauty
Revision of Civil Aeronautics Act
English in the new sixth
Discourse on method
Canadian Statement at Conference of the Law of the Sea.
Urban world/global city
Palace of Minos
Lecture on the pendulum-experiments at Harton Pit
The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data.
General mechanisms of resistance are discussed, including the drug resistance related proteins p glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein. Drug resistance in leukemia and lymphoma II. [R Pieters; G J L Kaspers; A J P Veerman;] Home. WorldCat Home About WorldCat Help.
Search. Search for Library Items Search for Lists Search for Contacts Search for a Library. Create lists Book\/a>, schema:CreativeWork\/a>. Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma.
The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research.
This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. This volume covers all important aspects of drug resistance in leukemia and lymphoma. General mechanisms of resistance are discussed, including the drug resistance related proteins, MRP (multi drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases, as well as drug-specific mechanisms of resistance.
Drug resistance in leukemia and lymphoma III by A. Veerman,Kluwer Academic/Plenum Press edition, in English. Overall, no significant change in clinical drug resistance has been demonstrated in solid tumors.1 In the more responsive tumors, leukemia, lymphoma, and myeloma, there are better than expected.
Drug Resistance in Leukemia and Lymphoma III by Gertjian J. Kaspers,available at Book Depository with free delivery worldwide. These are held every three years in Am sterdam, The Netherlands, since This book contains the proceedings of the third of these meetings, organised in The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data.
Buy (ebook) Drug Resistance in Leukemia and Lymphoma III by R. Pieters, G.J.L. Kaspers, A.J.P. Veerman, eBook format, from the Dymocks online bookstore. drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance. All together, the book contains more than 60 chapters with an extensive amount of information on all aspects of drug resistance in leukemia and lymphoma.
It can be recom mended to scientists, laboratory researchers, and clinicians. Type II inhibitors bind to the conformation coupled to the DFG-out position of the kinase AL (residues – in FLT3). 14 As previously noted, D is predicted to have a critical role in the.
Drug Resistance Testing of Acute Myeloid Leukemia in Adults Using the MT T Assay N. Stute, T. Köhler, L. Lehmann, W. Wetzstein, and G. Ehninger MTT Assay for Drug Resistance in Childhood Acute Leukemia and Effect o f Cyclosporin and Interferon: A Preliminary Report Zeynep Karaka.5, Leyla Agaoglu, Serap Erdem, Sema Anak.
Published: 09 December CDdirected therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. 1. Introduction. Chronic lymphocytic leukemia (CLL) is an incurable clonal proliferation of small CD5/CDpositive lymphocytes accumulating in blood, bone marrow and lymphoid tissues accounting for approximately 25% of all leukemias in Europe and North America [1,2].The median age of diagnosis is 70 years, and the disease is incurable in majority of.
DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III Edited by G. Kaspers R. Pieters and A. Veerman University Hospital Vrije Universiteit Amsterdam, The Netherlands KLUWER ACADEMIC / PLENUM PUBLISHERS NEW YORK, BOSTON, DORDRECHT, LONDON, MOSCOW.
Language: English ISBN:MeSH: Antineoplastic Agents; Drug Resistance; Leukemia/drug therapy*; Lymphoma/drug therapy Publication Type(s): Congresses Notes: Includes bibliographical references and indexes.
To go beyond that limit will require cracking the mystery of drug resistance, which occurs in about 20 percent of children with leukemia — and more than 50 percent of adults. It is the biggest reason leukemia still kills. Like the well-known problem of microbial resistance to antibiotics, leukemia drug resistance is evolution in action.
Researchers from Moffitt Cancer Center and Dana-Farber Cancer Institute have discovered a mechanism of drug resistance to Venetoclax (ABT) a BCL-2 targeting drug commonly used to treat chronic lymphocyte leukemia and acute myeloid leukemia.
Gaur S, Chen L, Yang L, Wu X, Un F, Yen Y. Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors.
Cancer Lett. ;(1)– Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today.
Written by international experts in the field, this volume examines clinical studies on topics such as:tyrosine kinase inhibitors, histon deacetyla. Researchers have discovered a mechanism of drug resistance to Venetoclax®, also known as ABT, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid.
A small molecule drug may help to overcome resistance to Imbruvica (ibrutinib) in patients with mantle cell lymphoma (MCL), according to preclinical study findings from The University of Texas MD Anderson Cancer Center.
“There is potentially a new therapeutic option for these patients that had very limited options previously,” said Dr. Krystle Nomie, from the Department of Lymphoma .T-cell acute lymphoblastic leukemia (T-ALL) is a progressive and invasive malignant neoplasm that occurs due to impaired function of oncogenes.
1 Although new therapeutic strategies have increased patient survival, there is still resistance to treatment that results in the death of some patients.
2 Lack of identification of molecular pathways involved in the proliferation and .